Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2024) [Under Japanese GAAP]May 10, 2024
Tokyo Stock Exchange
Company name: KYORIN Pharmaceutical Co., Ltd.
Code number: 4569
Web site: https://www.kyorin-pharm.co.jp/
Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer
Contact: Sakurou Banba, Director, Finance & Accounting
TEL 03-6374-9704
Scheduled date for Ordinary General Meeting of Shareholders: June 21, 2024
Scheduled date for starting dividend payment: June 5, 2024
Scheduled date for submitting securities report: June 24, 2024
(Amounts rounded down to the nearest million yen)
1. Consolidated Results for the Fiscal Year Ended March 31, 2024 (From April 1, 2023, to March 31, 2024)(1) Consolidated Operating Results(Percentage changes relative to previous corresponding period)
Profit attributable toNet sales
Operating profit
Ordinary profit
owners of parent
Fiscal year ended Million yen% Million yen% Million yen% Million yen%March 31 2024
119,532
5.5
6,013
17.4
6,602
13.3
5,322
12.7
March 31 2023
113,270
7.3
5,123
2.3
5,827
4.6
4,723
20.1
(Note) Comprehensive income: For the fiscal year ended March 31, 2024: 7,949 million yen (99.4%),
For the fiscal year ended March 31, 2023: 3,986 million yen (10.0%)

Basic earnings
per share

Fiscal year ended
March 31, 2024
March 31, 2023

Diluted earnings
per share

Return on equity

Ratio of ordinary
profit to total assets

Ratio of operating
profit to net sales

Yen
——%
4.2
3.8%
3.7
3.3%
5.0
4.5

Yen
92.74
82.44(Note) Share of loss(profit) of entities accounted for using equity method: For the fiscal year ended March 31, 2024: －12 million yen,
For the fiscal year ended March 31, 2023: －0 million yen(2) Consolidated Financial Position
Total assets
As ofMillion yen
March 31, 2024
177,679
March 31, 2023
176,045

Net assets
Million yen
130,783
125,461

Equity ratio%
73.6
71.3

Net assets per shareyen2,276.52
2,189.40(Note) Equity: As of March 31, 2024: 130,783 million yen, As of March 31, 2023: 125,461 million yen(3) Consolidated Cash Flows
Cash flows fromoperating activities
Fiscal year ended
Million yen
March 2024
1,549
March 2023
2,008

Cash flows frominvesting activities
Million yen－3,187－6,275

Cash flows from
Cash and cash equivalents
financing activities
at the end of year
Million yen
Million yen
13,886－3,347
18,816－3,363

2. Dividends
Total cash
dividends(Total)Annual dividends per share(Record date)Fiscal year ended
March 31, 2023
Fiscal year ended
March 31, 2024
Fiscal year ending
March 31, 2025(Forecast)FirstSecondThird
Fiscalquarter-end quarter-end quarter-end year-end

Total

Yen

Yen

Yen

Yen

Yen Million Yen

—

20.00

—

32.00

52.00

—

20.00

—

32.00

52.00

—

20.00

—

32.00

52.00

1

Ratio of
Payout ratio dividends to(Consolidated) net assets(Consolidated)

%%

3,023

64.0

2.4

3,023

56.8

2.3

60.5

3. Forecast of Consolidated for the Year Ending March 31, 2025 (From April 1, 2024, to March 31, 2025)(Percentage changes relative to previous corresponding period)
Profit attributable to Earnings
Net sales
Operating profit
Ordinary profit
owners of parent
per share
Million yen% Million yen% Million yen% Million yen%Yen
First half
56,9003.6
1,000 －12.6
1,300
900 －48.8
15.67
－6.3
Full year
123,400
3.2
6,500
8.1
6,900
4.5
5,000
87.03
－6.1

4. Other(1) Changes in major subsidiaries during the period(Change of specified subsidiaries associated with a change of the scope of consolidation): Yes
Newly included: None
Excluded:
1 company (The former Kyorin Pharmaceutical Co., Ltd.)(2) Changes in accounting policies, changes in accounting estimates and restatements(i) Changes due to mandatory changes of accounting standards: None(ii) Changes other than i): None(iii) Changes in accounting estimates: Yes(iv) Restatements: None(3) Number of shares issued (common stock)(i) Number of shares issued and outstanding at the end of the fiscal year (including treasury stock)
Fiscal year ended March 31 2024: 64,607,936 shares,
Fiscal year ended March 31 2023: 64,607,936 shares(ii) Number of shares of treasury stock at the end of the fiscal year
Fiscal year ended March 31 2024: 7,159,151 shares,
Fiscal year ended March 31 2023: 7,304,066 shares(iii) Averaged number of shares of during the period
Fiscal year ended March 31 2024: 57,389,377 shares,
Fiscal year ended March 31 2023: 57,303,071 shares* This financial report is not subject to audit procedures by Certified Public Accountants or audit firm.
* Explanations about the appropriate use of the business forecasts and other noteworthy points.
These forecast performance figures are based on information currently available to the Company and may include
uncertain factors or risk that affect our future performance. Accordingly, actual business results may materiallydiffer from the forecasted figures due to various factors in the future.
(Methods for obtaining supplementary materials and content of financial results disclosure)
Supplementary materials will be made available on the Company’s website in conjunction with the Summary ofConsolidated Financial Results.

2